The identification of a tumour marker which is highly sensitive as well as specific for lung cancer, and can be assayed by simple, reproducible and cheap techniques, remains elusive. In addition, accurate measurement of the tumour marker should either replace or provide further significant information to existing staging investigations, ideally reflecting tumour mass, correlating with prognosis and finally be useful in monitoring therapy.
Neuron specific enolase (NSE) is a glycolytic enzyme found in the brain, in a variety of amine precursor uptake and decarboxylation (APUD) enzyme system containing cells, in neuroendocrine cells, and has been identified in large amounts in neuroendocrine tumours including small cell lung cancer (Tapia et al., 1981) . Carney et al. (1982) performed a prospective study on 96 patients with small cell lung cancer (SCLC). Sixty-nine per cent of all patients had elevated serum levels of NSE, 39% of those with limited stage disease (LD) and in 87% with extensive disease (ED). NSE levels returned to normal in all patients who achieved complete remission, and rose again with relapse. Failure of NSE levels to return to normal was associated with continuous disease activity. Similar findings have been reported in other studies Kato et al., 1983; Johnson et al., 1984; Pahlman et al., 1984; Akoun et al., 1985; Esscher et al., 1985) . Thus measurements of NSE may provide additional information in small cell lung cancer for staging purposes, following disease activity, sub-clinical relapse and monitoring therapy. These studies have shown that serum NSE levels are less often raised in non-small cell lung cancer (NSCLC), 18% compared to 75% in SCLC, indicating that NSE may be useful in differentiating SCLC from other lung tumours. However, there is considerable debate on the histogenesis of lung carcinoma and on the neuroendocrine distinction between SCLC and NSCLC. Most tumours can be designated to a morphological type such as squamous, small cell, adeno or large cell carcinoma. But some tumours express a combination of these appearances in different parts of the tumour (Willis, 1948) and also within the same tumour cell (McDowell & Trump, 1981) . The biological distinction Correspondence: N. Thatcher. Received 8 February 1988; and in revised, form, 24 June 1988. between SCLC and NSCLC shows considerable overlap (Gazdar et al., 1983) , and in particular, the neural characteristics as expressed in SCLC by NSE (in serum or immunohistochemistry) appear in other non-small cell tumours (Sidhu, 1980; Baylin et al., 1982; Dhillon et al., 1985) . Similar results for serum NSE levels in SCLC have been obtained using different radioimmunoassays (Carney et al., 1982; Ariyoshi et al., 1983; Johnson et al., 1984; Pahlman et al., 1984; Akoun et al., 1985; Cooper et al., 1985) . However, in NSCLC Ariyoshi et al., 1983; Pahlman et al., 1984; Cooper et al., 1985 commented on the high serum NSE levels found in large cell tumours within their series of NSCLC patients and the difficulty in distinguishing histologically these tumours from SCLC. Carney (1987) (West et al., 1962; Schwartz et al., 1985) . PHI is widely distributed in human tissue, and is a glycolytic enzyme abundantly found in liver and skeletal muscle. West et al. (1962) (Gropp et al., 1980) (Levinson et al., 1984) Determination of phosphohexose isomerase This enzyme catalyses the reversible reaction between fructose-6-phosphate and glucose-6-phosphate. The serum samples were stored at 4°C and the enzyme activity was measured at 37°C by the increase in absorbance at 340 nm by the conversion of glucose-6-phosphate to 6-phosphogluconate in the presence of glucose-6-P-dehydrogenase and NADP compared to a blank Tris buffer using a spectrophotometer (Rowan, 1978) .
Determination of circulating immune complexes Serum samples were stored at -80°C and when required CC were extracted from each serum sample after precipitation with polyethylene glycol. The precipitates were washed twice and redissolved in buffer before reaction with 1251 labelled anti-human IgG. CC levels were measured by determining the difference in the light scatter between the test and a blank normal serum solution using a Hyland nephelometer PDQ instrument. The light scattered by the antigen-antibody complexes was displayed as the % relative light scatter using a helium neon light source of wavelength 632.8 nm (Krapf et al., 1982; Levinson et al., 1984) . (Table III) . In forty-one patients with SCLC, (Table III) , 19 patients with limited disease had significantly elevated (P<0.05) CC levels (median value 52mgl-1, range 2-154mgl-1) compared to 22 patients with extensive disease (median value 41 mgl-', range 4-102mgl-1). There was no significant difference in the levels of CC between those patients with limited and extensive disease in NSCLC (Figure 3 ).
Results

Controls
Liver function tests For SCLC and NSCLC there was no significant difference in alkaline phosphatase (AP), gamma-aminotranspeptidase (GGT), aspartate-aminotransferase (AST) and lactic dehydrogenase (LDH) values as shown in Table IV . However, in those patients with SCLC and extensive disease AP (median 145.5 IU1-1), GGT (median 83.5 IU 1-l) and AST (median 35 IU -1) were increased significantly compared to those with limited disease: AP, median 96IU1-l (P<0.01), GGT, median 361U1 (P<0.01), and AST, median 23.4IU1 (P<0.05) using Mann-Whitney Wilcoxson Rank Sum Tests.
In NSCLC serum albumin was significantly lower median 34.7 g 1-1 compared to SCLC, median 40 g 1-1 (P <0.005), (Table IV) Survival curves were calculated following the method of Kaplan & Meier (1958) and significance tests based on logrank analysis (Kaplan et al., 1958; Peto et al., 1977) . To determine the most significant pre-treatment variables which were related to survival, Cox's proportional hazard model (1972) was used. A forward stepwise progression procedure being employed to determine combinations of patients characteristics which were important for predicting survival. A significance level of 5% was set as the limit for inclusion in the model.
The effect on survival of each of 32 pre-treatment variables was assessed and the results of the first step analysis are summarised in Table VII al., 1983; Ariyoshi et al., 1983; Pahlman et al., 1984; Akoun et al., 1985; Esscher et al., 1985; Cooper et al., 1985) have demonstrated significantly higher levels of NSE in SCLC compared to other forms of lung cancer, with significant elevation of serum levels of NSE in patients with extensive compared to limited disease in SCLC. These observations were confirmed in our study, however, the median serum values of NSE in those patients with SCLC and extensive disease were higher than in limited disease but did not achieve statistical significance. Elevated serum levels of NSE (>12.5ngml1) were observed in 41% (13/32) in our patients with NSCLC compared to 18% (45/254) in previous studies Pahlman et al., 1984; Akoun et al., 1985; Cooper et al., 1985; Esscher et al., 1985) . Interpretation of raised serum NSE levels in SCLC and NSCLC depend upon accurate histological classification, the neuroendocrine properties expressed by the tumour, and the upper limit of normal for NSE set for by the type of radioimmunoassay used. Further comparison of serum NSE values in NSCLC show that 77% were raised in the range 13-25ngml-1 in our study and in 69% in previous studies, with 23% and 31% respectively >25ngml-'. The use of a more discriminative upper limit for NSE of >25 ng ml-will result in a decreased sensitivity and a higher specificity. Overall NSE as a tumour marker in lung cancer is potentially useful in SCLC in assessing disease extent, monitoring therapy and sub-clinical relapse, however, the pretreatment values were normal in 41 % of our SCLC patients and in up to 30% in previous studies. Further clinical studies are required in larger numbers of patients with NSCLC with regard to neuroendocrine behaviour and subsequent tumour response to therapy.
The median values of serum PHI in both SCLC and (West et al., 1962) 72% of 126 patients with lung cancer had elevated serum levels of PHI with higher values occurring in those with distant metastasis. Bodansky (1954) had previously observed a close correlation of serum PHI and the presence of bone and hepatic metastases in carcinoma breast. Conflicting views (Schwartz et al., 1985; d'Eril et al., 1986) have been expressed on the specificity and sensitivity of PHI in lung cancer. Schwartz et al. (1985) stated that in 77 patients with lung cancer PHI exhibited a high sensitivity in detecting lung cancer with good specificity for normal subjects and in patients with benign lung tumours, but was less specific in benign respiratory diseases. Forty-four patients with SCLC had the highest values for PHI and the levels in those patients with localised disease were not significantly different from patients with advanced disease, and suggested that PHI may be a useful marker in the early detection of lung cancer. In contrast, d'Eril et al. (1986) stated that PHI in lung cancer had only fair sensitivity and a very low specificity, in that the mean values of PHI were similar to other neoplasms and other nonneoplastic respiratory diseases, and there was no significant difference in the mean values between early and metastatic lung cancer. Our study similarly showed that PHI could not differentiate the type of lung tumour or provide additional information for staging purposes.
In the present study, serum levels for CC were significantly higher in NSCLC, compared to SCLC. Gropp et al. (1980) reported that the incidence of CC using the % inhibition of Clq binding uptake was similar in the different histological types of lung cancer in 100 patients. Their study also demonstrated higher levels of CC in 75% of patients with metastases in contrast to only 25% in those with localised disease. Similar observations have been made in acute leukaemia, lymphoma and other solid tumours (Heimer & Klevi, 1976; Theofilopoulus et al., 1976; Teshima al., 1977) . In contrast, we have not shown significantly higher levels of CC in patients with lung cancer and extensive disease. The assay for CC employed in this study has been previously shown (Levinson et al., 1984) to correlate highly with Clq binding technique, and therefore technique seems unlikely to explain the differing results.
It was evident that in the 41 patients with SCLC, the median values of AP, GGT and AST were significantly elevated in those patients with extensive disease compared to those with limited disease. The levels of GGT, alkaline phosphatase and oxidative liver enzymes have been observed previously to rise at a relatively late stage of tumour dissemination (West et al., 1962; Neville & Cooper, 1976) .
The levels of NSE, PHI and CC did not correlate with the bulk of disease (i.e. the number of metastatic sites involved). The use of other tumour markers (ACTH, calcitonin and CEA) may allow a better correlation with the extent of disease (Havemann et al., 1985) . A recent study by Cooper et al. (1987) in SCLC showed that NSE was a more sensitive indicator of disease activity and monitoring therapy compared to CEA and acute phase proteins.
The pre-treatment serum values of the tumour markers NSE, PHI and CC did not predict the patients' response to therapy and were not significant prognostic factors. A greater proportion of patients with an elevated AP or GGT were non-responders, and a greater proportion of patients who went into complete remission or partial response had serum levels of AP or GGT within their normal range or a serum albumin >35gl-1. Other individual haematology or biochemical indices at presentation were not predictive factors for response to therapy in the 69 evaluable patients with lung cancer. However, the presence of more than 7 abnormal indices was significantly associated with a greater proportion of non-responders, and conversely a greater proportion were complete responders and partial responders when the number of abnormal indices was less than 7.
Only two out of 32 pre-treatment variables were significantly related to prognosis after evaluation in a multiple regression analysis, although other variables, e.g., tumour stage, serum albumin, alkaline phosphatase, etc., were significant on univariant analyses, but the presence of more than four abnormal indices and liver metastasis were the only important, independent variables. Once they had been included in the model no other variable contained any significant additional prognostic information.
In our study, the presence of 4 abnormal indices was the most important prognostic factor after evaluation in a multiple regression analysis and it was not possible to identify which combination of individual haematological and biochemical variables specifically affected survival due to the small numbers involved. However, as in previous studies (Cohen et al., 1981; Souhami et al., 1985; Cerny et al., 1987) the use of simple laboratory parameters provide as much information for prognosis as the other staging procedures of scans, bone marrow, etc. Cohen et al. (1981) identified a high plasma albumin and haemoglobin as the most influential prognostic factors in 56 patients with SCLC. Souhami et al. (1985) analysed 371 patients with SCLC and reported Karnofsky performance score, serum albumin, sodium, alkaline phosphatase and disease extent as independently significantly related to survival. Similarly, our own group (Cerny et al., 1987) found lactic dehydrogenase, sodium, Karnofsky performance score, alkaline phosphatase, tumour stage and bicarbonate, as important prognostic factors in 407 patients with SCLC. The presence of liver metastasis was the next most important independent pre-treatment variable in our present study (P<0.008). Ihde et al. (1981) stated that the median survival progressively worsened with increasing number of metastatic sites, and that metastasis to liver and brain significantly shortened survival in 106 patients with SCLC treated with chemotherapy. Similar observations on the presence of hepatic metastasis on survival have been made in both treated and untreated lung cancer patients (Zelen, 1973; Lanzotti et al., 1977) .
Earlier studies using univariate analysis reported performance score and extent of disease as the most important prognostic factors in lung cancer (for review, Stanley, 1985) , but included only a few of the plethora of patient factors which may provide pertinent information in the assessment of survival. More recent studies (Cohen et al., 1981; Souhami et al., 1985; Cerny et al., 1987) have shown that the inclusion of standard haematological and biochemical indices and clinical features are required in a multiple regression analysis for predicting survival in lung cancer. The present study has shown that NSE, PHI and CC as pre-treatment biological markers did not provide any additional information to existing staging investigations nor predict the response to therapy or the outcome in this group of 73 patients with lung cancer. The number of abnormal routine laboratory parameters was the most important prognostic factor.
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